HIV gene therapy shows promise in Phase II
This article was originally published in Scrip
The first Phase II gene therapy trial for treating HIV has shown some positive results, despite failing to meet its primary endpoint, according to a study by the University of California, Los Angeles, published online in the journal Nature Medicine on February 15th.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.